Frontiers in Immunology (May 2024)
Machine learning in the prediction of immunotherapy response and prognosis of melanoma: a systematic review and meta-analysis
Abstract
BackgroundThe emergence of immunotherapy has changed the treatment modality for melanoma and prolonged the survival of many patients. However, a handful of patients remain unresponsive to immunotherapy and effective tools for early identification of this patient population are still lacking. Researchers have developed machine learning algorithms for predicting immunotherapy response in melanoma, but their predictive accuracy has been inconsistent. Therefore, the present systematic review and meta-analysis was performed to comprehensively evaluate the predictive accuracy of machine learning in melanoma response to immunotherapy.MethodsRelevant studies were searched in PubMed, Web of Sciences, Cochrane Library, and Embase from their inception to July 30, 2022. The risk of bias and applicability of the included studies were assessed using the Prediction Model Risk of Bias Assessment Tool (PROBAST). Meta-analysis was performed on R4.2.0.ResultsA total of 36 studies consisting of 30 cohort studies and 6 case-control studies were included. These studies were mainly published between 2019 and 2022 and encompassed 75 models. The outcome measures of this study were progression-free survival (PFS), overall survival (OS), and treatment response. The pooled c-index was 0.728 (95%CI: 0.629–0.828) for PFS in the training set, 0.760 (95%CI: 0.728–0.792) and 0.819 (95%CI: 0.757–0.880) for treatment response in the training and validation sets, respectively, and 0.746 (95%CI: 0.721–0.771) and 0.700 (95%CI: 0.677–0.724) for OS in the training and validation sets, respectively.ConclusionMachine learning has considerable predictive accuracy in melanoma immunotherapy response and prognosis, especially in the former. However, due to the lack of external validation and the scarcity of certain types of models, further studies are warranted.
Keywords
